Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivothym: nivolumab + ipilimumab in previously treated thymic epithelial tumors
2023-508658-24-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in thymoma and thymic carcinoma (TC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 6 months. Planned start Aug 2024; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on 2023-508658-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508658-24-00.